GSK plc

GSK plc Gross Margin

The Gross Margin of GSK plc (GSK.L) as of Nov 2, 2026 is 72.54 %. In the previous year, Gross Margin was 69.80 % — a change of 3.93% (higher).

Gross Margin

72.54 %

YoY

3.93%

Last updated:

Gross Margin of GSK plc is 2025 72.54 % . Gross Margin of GSK plc was 2024 69.80 % . It decreases by 3.93% higher compared to the previous year.

For GSK plc, the gross margin of 72.5% is up versus 66.2% a few years ago.

The GSK plc Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
67.89 GBP
Jan 1, 2019
67.80 GBP
Jan 1, 2020
67.81 GBP
Jan 1, 2021
66.18 GBP
Jan 1, 2022
66.37 GBP
Jan 1, 2023
70.07 GBP
Jan 1, 2024
69.80 GBP
Jan 1, 2025
72.54 GBP
The GSK plc Gross Margin history
YEARGross MarginYoY
72.54 %+3.93%
69.80 %-0.39%
70.07 %+5.58%
66.37 %+0.29%
66.18 %-2.41%
67.81 %+0.02%
67.80 %-0.14%
67.89 %+2.03%
66.54 %+0.65%
66.11 %+5.39%
62.73 %-7.25%
67.63 %+9,692.17%
0.69 %-2.08%
0.71 %-1.04%
0.71 %-2.12%
0.73 %-2.51%
0.75 %-0.59%
0.75 %-1.42%
0.76 %-2.81%
0.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Gross Margin of GSK plc is 72.54 % in 2025.

Gross Margin of GSK plc changed from 69.80 % to 72.54 %, representing a 3.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin GSK plc since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's GSK plc with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — GSK plc

All Key Metrics — GSK plc